Helen-Cara Younan

Helen-Cara Younan

Auto-generated profile, based on publicly available information

Helen-Cara Younan

Department of Clinical Oncology, Imperial College Healthcare NHS Trust, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in Journal of the Royal Society of Medicine
Verified
Journal Article
Open access
PDF file
HYHelen-Cara Younan
Helen-Cara Younan
CJCornelia Junghans
Cornelia Junghans
MHMatthew Harris
Matthew Harris
AMAzeem Majeed
Azeem Majeed
SGShamini Gnani
Shamini Gnani

18 August 2020 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
MMMatthew Machin
Matthew Machin
HYHelen‐Cara Younan
Helen‐Cara Younan
ASA. A. P. Slesser
A. A. P. Slesser
YMYasser Mohsen
Yasser Mohsen

4 October 2020 in Phlebology: The Journal of Venous Disease
Verified
Journal Article
Open access
PDF file
MMM Machin
M Machin
HYHc Younan
Hc Younan
SSS Smith
S Smith
SSSafa Salim
Safa Salim
ADAh Davies
Ah Davies
JSJ Shalhoub
J Shalhoub
Objectives: The aim of this systematic review is to assess the performance of graduated compression stockings (GCS) in comparison to no venous thromboembolism (VTE) prophylaxis in the prevention of hospital-acquired thrombosis in low-risk surgical patients undergoing short-stay procedures. Methods: Aligning with PRISMA guidelines, online databases MEDLINE and EMBASE, Cochrane Library® and trial registries were searched. Eligible articles reported the VTE rate in low-risk surgical patients either receiving GCS or no VTE prophylaxis. Results: Narrative synthesis was performed on a single eligible article. The included study arm consisted of participants undergoing knee arthroscopy with the use of GCS alone reporting a total of 29 VTE events (4.4%), 16 of which were asymptomatic DVTs (2.4%). Conclusion: There is a complete lack of evidence to support the use of GCS in the prevention of HAT for low-risk surgical patients. An adequately powered trial is required to provide level-IA evidence to support this practice.

4 January 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
HYHelen-Cara Younan
Helen-Cara Younan
GKGeorgina Keogh
Georgina Keogh
MSMichael Seckl
Michael Seckl
NSNaveed Sarwar
Naveed Sarwar
We present a case of a woman in her 20s, with a prior history of paediatric sacrococcygeal germ cell tumour, presenting with a 6-month history of perianal pain. An MRI pelvis revealed a heterogeneous soft tissue mass causing destruction of the sacrococcygeal bone. A staging CT demonstrated metastatic deposits in the lungs and hypodense foci in the liver suspicious of metastatic disease. Her alpha-fetoprotein levels were raised and a CT-guided biopsy was in keeping with recurrent germ cell tumour. She was referred to a national centre for the treatment of germ cell tumours in adults and was rechallenged with cisplatin-based multiagent chemotherapy with a curative intent. This case raises the important question of how long we should follow-up these patients and whether they can ever be safely discharged from oncology surveillance.

10 February 2022 in Lung Cancer
Verified
Journal Article
Closed access
HYHelen-Cara Younan
Helen-Cara Younan
ZSZhang Shuai
Zhang Shuai
MMMaria Monroy
Maria Monroy
MAManar Almusarhed
Manar Almusarhed
MJMax Julve
Max Julve
DJDebra Josephs
Debra Josephs